Oral GLP-1 Medications: Wegovy Pill vs Foundayo (Orforglipron) Cost Comparison 2026

Last updated: May 28, 2026

For most of the GLP-1 era, "weight-loss GLP-1" meant an injection. That changed in early 2026, when two oral options reached the U.S. market: Novo Nordisk's Wegovy tablet (oral semaglutide, approved January 2026) and Eli Lilly's Foundayo (orforglipron, approved April 1, 2026). Both are taken once daily, both are FDA-approved for weight management, and both have launched with self-pay starter prices that are meaningfully lower than what injectable Wegovy and Zepbound cost at the start of treatment.

This guide compares them head-to-head on cost and clinical profile, then puts them in context against the injectable formulations. We'll be specific about where oral pills are cheaper, where prices converge, and where the practical tradeoffs aren't really about cost at all.

The Shift From Injection to Pill

The two oral GLP-1s now available for weight management are fundamentally different molecules using the same biological target:

• Wegovy tablet (semaglutide) — approved January 2026 by Novo Nordisk. It's the first oral GLP-1 approved specifically for weight management. The molecule itself is the same peptide semaglutide in injectable Wegovy and Ozempic, packaged for oral delivery.
• Foundayo (orforglipron) — approved April 1, 2026 by Eli Lilly. It's the first GLP-1 pill with no food or water restrictions — a practical advantage worth taking seriously. Chemically, it's a non-peptide small molecule (most GLP-1s are peptides), which is what enables the relaxed dosing window.

Why this matters for cost: oral formulations have launched at lower self-pay entry prices than injectables, and active competition between Novo Nordisk and Lilly is pushing prices down. Novo Nordisk has already announced a 50% list price reduction for both oral and injectable Wegovy effective January 1, 2027. We'll come back to what that means for planning.

Head-to-Head Comparison Table

Cost Breakdown — Oral vs. Injectable

If you're choosing between an oral and an injectable formulation, here's how the costs line up across self-pay, commercial-insurance, and Medicare pathways:

Key takeaway: at entry-level doses, oral formulations are meaningfully cheaper for self-pay patients — sometimes by $200+/month. At maintenance doses, prices converge. The biggest cost advantage of going oral is at the start of treatment.

January 2027 list-price reduction: Novo Nordisk has announced a 50% list price cut for both oral and injectable Wegovy effective January 1, 2027. That changes the long-term math meaningfully — the WAC ceiling drops from $1,349/month toward roughly $675/month, which will pull insurance-negotiated rates and uninsured cash prices down over the months following. If you're weighing oral vs. injectable purely on cost and you're not in a hurry, the January 2027 transition is worth factoring in.

Should You Switch From Injectable to Oral?

This is one of the most common questions from current GLP-1 users. The honest answer: sometimes yes, sometimes no. Here's the framework.

The clinical evidence supports switching

The ATTAIN-MAINTAIN trial specifically studied switching from injectables to oral orforglipron:

• Patients switching from injectable semaglutide to oral orforglipron maintained 79.3% of their prior weight loss.
• Patients switching from injectable tirzepatide to orforglipron maintained 74.7%.

Switching is done under physician supervision with dose titration restarting at the lowest oral dose. It's not a one-for-one swap — expect to step back up to a comparable steady-state dose over several weeks.

Cost reasons to switch

• If you're self-paying and at a starter dose, the oral starter is cheaper.
• If your insurance covers one formulation but not the other, switching could swap a $200–$400/month cash price for a $25 copay.
• If you're on Medicare and qualify for the Bridge, both oral medications are covered at $50/month — the same as the covered injectable Wegovy and Zepbound (KwikPen).

Convenience reasons to switch

• No injection anxiety — meaningful for needle-averse patients who've avoided GLP-1s entirely.
• Easier to travel with — no temperature-sensitive shipping, no needle disposal logistics.
• Foundayo has no food restrictions — you don't have to plan your morning around a 30-minute pre-meal window.

Reasons NOT to switch

• You're on a stable injectable dose with good results and insurance coverage. Switching resets titration and there's no guarantee the oral formulation will produce equivalent results for you.
• Maximum efficacy matters more than convenience. Wegovy injectable (and especially Zepbound injectable, which has shown 20–22% weight loss in trials) outperforms Foundayo's 12.4% average. If you're targeting the highest efficacy, the injectables still lead.

Bottom line: Talk to your doctor. Switching purely for cost makes sense in specific scenarios — not all of them.

Where to Get Oral GLP-1 Medications

There are three realistic pathways, and the right one depends on whether you have a doctor relationship, insurance coverage, and how much fee-stacking you're willing to put up with.

1. Your doctor + retail pharmacy. The traditional route. Works with insurance or self-pay. Best when you already have a primary care relationship and your plan covers the medication. Both Wegovy tablet and Foundayo are available at 70,000+ U.S. pharmacies including CVS, Walgreens, Walmart, and Costco.
2. Telehealth providers. Ro, Hims, Noom Med, and others now offer oral GLP-1 prescriptions through their existing intake flows. Convenient if you don't have a doctor relationship or want home delivery. Compare current prices in our GLP-1 cost comparison tool — it shows the all-in price including any membership / consultation / shipping fees on each provider, sorted by total monthly cost.
3. Direct from manufacturer. Foundayo ships via LillyDirect with free home delivery. Wegovy is available through NovoCare's self-pay program at the prices in the table above. Manufacturer-direct can be the cheapest path for self-pay starter doses.

For Medicare beneficiaries: both oral medications are covered under the Medicare GLP-1 Bridge Program at $50/month starting July 1, 2026. If you're on Medicare and considering an oral GLP-1, the Bridge will almost certainly be the cheapest pathway if you qualify. Our free Bridge eligibility checker walks through the criteria in about a minute.

What About Other Oral GLP-1 Options?

Brief tour of what else exists, what's coming, and what's been shelved:

• Rybelsus (oral semaglutide 3 / 7 / 14 mg) is FDA-approved for type 2 diabetes only, not weight loss. Lower doses than Wegovy tablet. Sometimes prescribed off-label for weight loss but insurance typically won't cover it for that indication. If your goal is weight loss specifically, Wegovy tablet is the on-label option.
• Pfizer's danuglipron — development was discontinued after a participant experienced potential drug-induced liver injury. Don't expect this in the near-term U.S. market.
• Structure Therapeutics GSBR-1290 — currently in Phase 2/3 trials, not yet approved.
• No generic oral GLP-1s are available as of May 2026. Semaglutide composition patents in the U.S. don't expire for several more years; orforglipron is a brand-new Lilly molecule with much longer patent protection ahead.

Translation: if you're choosing an oral GLP-1 for weight loss right now, it's effectively Wegovy tablet vs. Foundayo. That's likely to be the choice through at least 2027.

The Bottom Line

A clear recommendation framework, depending on your situation:

• If you're self-paying and starting treatment: oral formulations at $149/month are the most affordable entry point. Either Wegovy tablet or Foundayo at the starter dose works.
• If convenience matters: Foundayo has the practical edge — no food restrictions means you don't have to plan your morning around the medication.
• If maximum weight loss is the priority: the data favors Wegovy (oral 16.6%, injectable similar) over Foundayo (12.4%). Zepbound injectable still leads on efficacy in head-to-head comparisons (20–22%), but at higher cost.
• If you're on Medicare: check the Bridge Program — $50/month for either oral option starting July 2026. Take the eligibility checker first.
• For everyone: use the comparison tool to find the lowest all-in price across telehealth providers — including any membership, consultation, and shipping fees that don't appear in the headline price.

Frequently Asked Questions

How much does the Wegovy pill cost without insurance?

The Wegovy oral tablet starts at $149/month for the 1.5 mg and 4 mg doses through NovoCare and GoodRx, and runs $299/month for the 9 mg and 25 mg maintenance doses. Unsubsidized list price is $1,349/month. Novo Nordisk has announced a 50% list-price cut effective January 1, 2027, which will affect cash and insurance-negotiated rates.

How much does Foundayo cost per month?

Foundayo starts at $149/month for the 0.8 mg starter dose and runs $299–$349/month for the 14.5 mg and 17.2 mg maintenance doses through Lilly's self-pay programs. It's available via LillyDirect with free home delivery. With commercial insurance + the Lilly Savings Card, copays can drop to as low as $25/month.

Is the Wegovy pill cheaper than the injection?

At starter doses, yes — $149/month tablet vs. roughly $199–$349/month for the injection on self-pay. At maintenance doses, prices converge to about $299/month for both. With insurance and the Novo Nordisk Savings Card, both can drop to about $25/month. The cost advantage is most pronounced at the start of treatment.

Can I switch from injectable to oral GLP-1 medication?

Yes, under physician supervision. The ATTAIN-MAINTAIN trial showed patients switching from injectable semaglutide to oral orforglipron maintained 79.3% of their prior weight loss; from injectable tirzepatide to orforglipron, 74.7%. Switching restarts dose titration at the lowest oral dose. Talk to your doctor before changing — switching purely for cost makes sense in some scenarios, not all.

Does Medicare cover oral GLP-1 pills?

Yes — both Wegovy tablet and Foundayo are covered under the Medicare GLP-1 Bridge Program at a flat $50/month copay starting July 1, 2026. The program runs through December 31, 2027 and requires meeting CMS eligibility criteria. Use our eligibility checker to find out in about a minute.

What is the difference between Wegovy pill and Foundayo?

Wegovy tablet is oral semaglutide (a peptide) from Novo Nordisk — must be taken on an empty stomach with no more than 4 oz of water, 30 minutes before eating. Foundayo (orforglipron) from Lilly is a non-peptide small molecule with no food restrictions. In clinical trials, Wegovy showed greater average weight loss (16.6%) than Foundayo (12.4%).

Do I need a prescription for oral GLP-1 medications?

Yes. Both Wegovy tablet and Foundayo are prescription-only. You can get a prescription through your primary care doctor, an endocrinologist or obesity-medicine specialist, or a telehealth provider that prescribes GLP-1s. They are not over-the-counter, and any source claiming otherwise should be considered illegitimate.

Sources & References

• Novo Nordisk — NovoCare self-pay program for Wegovy
• Eli Lilly — LillyDirect (Foundayo home delivery)
• FDA — FDA.gov for prescribing information and approval announcements
• OASIS 4 trial (oral semaglutide for weight loss); ATTAIN-1 trial (orforglipron for weight loss); ATTAIN-MAINTAIN trial (switching from injectables to orforglipron) — Novo Nordisk and Eli Lilly clinical trial publications
• Medicare.gov for Medicare GLP-1 Bridge details

Related Reading

• Wegovy Injection vs Pill: Cost Comparison — the deeper Wegovy-specific cost breakdown
• Foundayo Cost & Savings Guide — how to minimize Foundayo's monthly cost
• Cheapest Wegovy Without Insurance — all current Wegovy pathways ranked by cost
• Medicare GLP-1 Bridge Program 2026 Guide — full eligibility and enrollment details
• Medicare Bridge Eligibility Checker — 5 questions, instant result